193 related articles for article (PubMed ID: 12527933)
1. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K
Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
[TBL] [Abstract][Full Text] [Related]
2. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy.
Wang H; Dai J; Hou S; Qian W; Li B; Ma J; Fan X; Zhao J; Yang S; Sang H; Yang Q; Wang R; Guo Y
Cancer Gene Ther; 2005 Sep; 12(9):769-77. PubMed ID: 15877081
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma.
Schmitz V; Barajas M; Wang L; Peng D; Duarte M; Prieto J; Qian C
Hepatology; 2001 Jul; 34(1):72-81. PubMed ID: 11431736
[TBL] [Abstract][Full Text] [Related]
6. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y
Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators.
Peter I; Nawrath M; Kamarashev J; Odermatt B; Mezzacasa A; Hemmi S
Cancer Gene Ther; 2002 Jul; 9(7):597-605. PubMed ID: 12082460
[TBL] [Abstract][Full Text] [Related]
8. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
9. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer.
Noguchi M; Imaizumi K; Kawabe T; Wakayama H; Horio Y; Sekido Y; Hara T; Hashimoto N; Takahashi M; Shimokata K; Hasegawa Y
Cancer Gene Ther; 2001 Jun; 8(6):421-9. PubMed ID: 11498762
[TBL] [Abstract][Full Text] [Related]
10. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.
Nakajima A; Kodama T; Morimoto S; Azuma M; Takeda K; Oshima H; Yoshino S; Yagita H; Okumura K
J Immunol; 1998 Aug; 161(4):1901-7. PubMed ID: 9712059
[TBL] [Abstract][Full Text] [Related]
12. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy.
Wu JQ; Zhao WH; Li Y; Zhu B; Yin KS
Virology; 2007 Nov; 368(2):309-16. PubMed ID: 17675129
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered myeloma cell vaccine.
Hao S; Chan T; Xiang J
Methods Mol Med; 2005; 113():235-44. PubMed ID: 15968107
[TBL] [Abstract][Full Text] [Related]
18. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
Liu Y; Qureshi M; Xiang J
Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
20. Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats.
Hanyu K; Iida T; Shiba H; Ohashi T; Eto Y; Yanaga K
Anticancer Res; 2008; 28(5A):2785-9. PubMed ID: 19035311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
